NK cell expansion after primary multimodal treatment to predict progression free survival in inoperable stage III NSCLC. Management and treatment of patients with stage III unresected NSCLC at UPMC: A ...

"Clinicians performing tumor biopsy need to ensure that there’s adequate tissue for both diagnosis and NGS testing. Having immediate pathology review of biopsy specimens in the operating room can ...

Experts explain the presence and role of EGFR exon 20 insertion mutations in non–small cell lung cancer and highlight the role of molecular profiling. Estelamari Rodriguez, M.D., MPH: Hello, and ...

Association between patient tumour characteristics and five-year survival in Nigerian patients with breast cancer.

OBJECTIVES: Clinical practice guidelines recommend at least annual testing of estimated glomerular filtration rate (eGFR) and urine albumin-creatinine ratio (uACR) for patients with chronic kidney ...

The FINANCIAL — Insights from experts working on-the-ground in lung cancer, compiled by Boehringer Ingelheim, shed light on challenges faced by patients with advanced stage adenocarcinoma, a type of ...

EGFR mutation testing is crucial for NSCLC treatment, but global disparities exist in access to comprehensive molecular diagnostics. Third-generation inhibitors and combination regimens improve ...

CHICAGO -- Patients without disease progression following chemoradiotherapy for unresectable stage III non-small cell lung cancer (NSCLC) should receive osimertinib (Tagrisso) if they harbor EGFR ...

DEAR DR. ROACH: I am a 73-year-old female. A recent blood test returned an eGFR (estimated glomerular filtration rate) of 59. My physician’s nurse told me that the test was normal. When I asked her ...